Major Role for Amphotericin B–Flucytosine Combination in Severe Cryptococcosis
Authors:
- Françoise DromerFDFrançoise Dromer
- Didier GuillemotDGDidier Guillemot
- for the French Cryptococcosis Study GroupFGfor the French Cryptococcosis Study Group
Open Access
- 6 August 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (8) , e2870
Abstract
The Infectious Diseases Society of America published in 2000 practical guidelines for the management of cryptococcosis. However, treatment strategies have not been fully validated in the various clinical settings due to exclusion criteria during therapeutic trials. We assessed here the optimal therapeutic strategies for severe cryptococcosis using the observational prospective CryptoA/D study after analyzing routine clinical care of cryptococcosis in university or tertiary care hospitals. Patients were enrolled if at least one culture grew positive with Cryptococcus neoformans. Control of sterilization was warranted 2 weeks (Wk2) and 3 months (Mo3) after antifungal therapy onset. 208 HIV-positive or -negative adult patients were analyzed. Treatment failure (death or mycological failure) at Wk2 and Mo3 was the main outcome measured. Combination of amphotericin B+flucytosine (AMB+5FC) was the best regimen for induction therapy in patients with meningoencephalitis and in all patients with high fungal burden and abnormal neurology. In those patients, treatment failure at Wk2 was 26% in the AMB+5FC group vs. 56% with any other treatments (p<0.001). In patients treated with AMB+5FC, factors independently associated with Wk2 mycological failure were high serum antigen titer (OR [95%CI] = 4.43[1.21–16.23], p = 0.025) and abnormal brain imaging (OR = 3.89[1.23–12.31], p = 0.021) at baseline. Haematological malignancy (OR = 4.02[1.32–12.25], p = 0.015), abnormal neurology at baseline (OR = 2.71[1.10–6.69], p = 0.030) and prescription of 5FC for less than 14 days (OR = 3.30[1.12–9.70], p = 0.030) were independently associated with treatment failure at Mo3. Our results support the conclusion that induction therapy with AMB+5FC for at least 14 days should be prescribed rather than any other induction treatments in all patients with high fungal burden at baseline regardless of their HIV serostatus and of the presence of proven meningoencephalitis.Keywords
This publication has 38 references indexed in Scilit:
- Cryptococcal Neuroradiological Lesions Correlate with Severity during Cryptococcal Meningoencephalitis in HIV-Positive Patients in the HAART EraPLOS ONE, 2008
- Oral versus Intravenous Flucytosine in Patients with Human Immunodeficiency Virus-Associated Cryptococcal MeningitisAntimicrobial Agents and Chemotherapy, 2007
- Management of Cryptococcosis: How Are We Doing?PLOS Medicine, 2007
- Determinants of Disease Presentation and Outcome during Cryptococcosis: The CryptoA/D StudyPLOS Medicine, 2007
- In Vitro-Clinical Correlations for Amphotericin B Susceptibility in AIDS-Associated Cryptococcal MeningitisAntimicrobial Agents and Chemotherapy, 2007
- Combination of Amphotericin B with Flucytosine Is Active In Vitro against Flucytosine-Resistant Isolates of Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2007
- Results Obtained with Various Antifungal Susceptibility Testing Methods Do Not Predict Early Clinical Outcome in Patients with CryptococcosisAntimicrobial Agents and Chemotherapy, 2006
- The Changing Epidemiology of Cryptococcosis: An Update from Population‐Based Active Surveillance in 2 Large Metropolitan Areas, 1992–2000Clinical Infectious Diseases, 2003
- Practice Guidelines for the Management of Cryptococcal DiseaseClinical Infectious Diseases, 2000
- A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal MeningitisNew England Journal of Medicine, 1979